Screening modestly reduces prostate cancer deaths, review finds

Screening with PSA tests modestly reduces prostate cancer deaths, according to an updated Cochrane review. Read more at https://medicalxpress.com/news/2026-05-screening-modestly-prostate-cancer-deaths.html

Screening for prostate cancer using a PSA (prostate-specific antigen) blood test modestly reduces the risk of dying from the disease, according to an updated review published in the Cochrane Database of Systematic Reviews. This shift comes after previous reviews found insufficient evidence that screening reduced deaths.

The new analysis, which includes data from six trials involving almost 800,000 participants across Europe and North America, suggests that PSA screening can prevent approximately two prostate cancer deaths for every 1,000 men screened. Specifically, the review indicates that 500 men would need to be invited for screening to prevent one death.

Dr. Philipp Dahm, senior author from the University of Minnesota, emphasized, "With new data now available, we can now say with moderate certainty that PSA screening reduces prostate cancer deaths in men with a sufficient life expectancy." This finding provides stronger evidence for discussions about PSA screening among patients and healthcare providers.

However, it's important to note that while PSA screening shows modest benefits, the review also highlights potential downsides. The studies did not systematically assess quality of life impacts such as complications from biopsies, sexual dysfunction, or urinary problems. Dr. Dahm cautioned, "We want to be clear that this is not a blanket endorsement of universal screening. The decision should always be made between a patient and their doctor, with a full understanding of both the potential benefits and the very real risks of overdiagnosis and unnecessary treatment."

The review also examined newer approaches combining PSA testing with a kallikrein panel blood test and MRI scanning to detect more precise cancers that do not require aggressive treatments. These methods may lead to higher cancer detection rates but further research is needed to determine their long-term benefits.

Dr. Juan Franco from Heinrich Heine University Düsseldorf noted, "While the modest benefits observed in this review aren't due to a change in the underlying evidence, they are partly attributed to the longer follow-up periods of the trials." This suggests that as more data accumulates over time, the mortality benefit becomes clearer.

The landscape for prostate cancer screening has changed significantly since previous reviews. Not only do we have stronger long-term evidence on mortality rates, but tools like MRI and active surveillance have advanced, potentially reducing unnecessary treatments.

In conclusion, while PSA testing shows a modest reduction in prostate cancer deaths, it is crucial to weigh these benefits against the risks of overdiagnosis and overtreatment. Patients should make informed decisions with their healthcare providers based on comprehensive information about both options.